Home 2016-10-24T12:33:21+00:00
Slide thumbnail
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
Slide thumbnail
RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.
Slide thumbnail
The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.
Slide thumbnail
RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.
Slide thumbnail
NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for RadioMedix and Viewpoint.
Slide thumbnail
RadioMedix and Viewpoint MT secure a second SBIR NCI grant for image guided therapy for metastatic melanoma
AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors
RadioMedix Inc. launches SmartMedix™ synthesizers powered by Trasis in USA
Slide thumbnail
Viewpoint/Radiomedix Partner to Win SBIR Funding
RadioMedix initiates the first Ga-68 PSMA (ProstaMedix™) clinical trial for diagnosis and management of prostate cancer in U.S.
RadioMedix, Inc. Receives FDA Orphan Drug Designation for the 68Ga-DOTATATE (GalioMedix TM) for the management of the neuroendocrine tumors
RadioMedix Inc. granted exclusive distribution authorization for ITG 68Ge/68Ga generators, and ITG iQS® Ga-68 Fluidic Labelling Module in U.S.A.
RadioMedix Inc. is a co-sponsor and collaborator on the two IND clinical trials

Innovating Theranostics

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Recent News


2017-06-21T16:43:09+00:00

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

June 21st, 2017|Comments Off on RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

2017-06-19T17:17:32+00:00

RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.

June 19th, 2017|Comments Off on RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.

2017-02-22T17:50:24+00:00

The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

February 6th, 2017|Comments Off on The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

2016-11-02T12:49:38+00:00

RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.

October 31st, 2016|Comments Off on RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.

2016-10-24T12:33:22+00:00

RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)

October 18th, 2016|Comments Off on RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)

2016-10-24T12:33:22+00:00

RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.

August 23rd, 2016|Comments Off on RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.